Payar Radfar

Payar Radfar

Auto-generated profile, based on publicly available information

Payar Radfar

Smart MCs PTY LTD, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Trends in Biotechnology
Verified
Journal Article
Closed access
PRPayar Radfar
Payar Radfar
HEHamidreza Aboulkheyr Es
Hamidreza Aboulkheyr Es
RSRob Salomon
Rob Salomon
AKArutha Kulasinghe
Arutha Kulasinghe
NRNaveen Ramalingam
Naveen Ramalingam
MWMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani

1 January 2022 in Clinical & Translational Immunology
Verified
Journal Article
Open access
HRHabib Sadeghi Rad
Habib Sadeghi Rad
YSYavar Shiravand
Yavar Shiravand
PRPayar Radfar
Payar Radfar
RLRahull Ladwa
Rahull Ladwa
CPChris Perry
Chris Perry
AKArutha Kulasinghe
Arutha Kulasinghe
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5‐year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.

21 February 2025 in Trends in Biotechnology
Verified
Journal Article
Closed access
PRPayar Radfar
Payar Radfar

7 August 2025 in Biomedical Materials
Verified
Journal Article
Open access
TCTimothy R Cox
Timothy R Cox
DLDavid Lesmana
David Lesmana
COChristopher J O’kEeffe
Christopher J O’kEeffe
TLTin Lun Lam
Tin Lun Lam
WZWeibin Zou
Weibin Zou
LDLin Ding
Lin Ding
Large-scale cellular production systems offer a significant and diverse benefit impacting the therapeutic (stem cell and vaccine production) and cellular agriculture (lab-grown meat) sectors. Producing desired cells at mass can improve production yield whilst reducing the environmental and ethical burden associated with industrialised agriculture and production of therapeutic goods. Many existing large-scale cultivation strategies of adherent cells leverage the use of microcarriers (MCs) within bioreactors. However, currently commercial MCs are not dissolvable and lack specificity for different cell types and bioprocessing contexts. In this work, we validate the effectiveness of customisable, polymeric MCs engineered to enhance cell growth and productivity. These MCs, which can be adjusted in terms of stiffness, surface charge, and size, maintain their structural integrity while offering precise property modifications. Under specific bioprocessing conditions, the custom MCs demonstrated significant improvements in cell productivity and sustainability compared to other commercial options. Our study (1) highlights how tailored substrate properties, particularly stiffness, can significantly impact cell yield and outcomes, and (2) suggests additional optimisations in surface charge and size that could further enhance MC technology. These advancements have the potential to improve large-scale cell and virus production efficiency, ultimately reducing the cost of production.

27 March 2026 in Trends in Biotechnology
Verified
Journal Article
Closed access
PRPayar Radfar
Payar Radfar
DBDavid Burt
David Burt
KDKaveh Daneshvar
Kaveh Daneshvar